Sonia Fox
Cancer Research UK Clinical Trials Unit(GB)University of Birmingham(GB)
Publications by Year
Research Areas
Myeloproliferative Neoplasms: Diagnosis and Treatment, Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Hemoglobinopathies and Related Disorders, Kruppel-like factors research
Most-Cited Works
- → Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide(2017)165 cited
- → Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial(2023)129 cited
- → The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease(2019)32 cited
- → The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib(2019)20 cited
- → MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study(2022)13 cited
- → Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis(2023)9 cited
- → Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers(2019)7 cited
- → Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy(2022)5 cited
- → Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial(2022)5 cited
- → Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high‐risk acute myeloid leukaemia ineligible for intensive chemotherapy(2021)4 cited